CDC:US Platform to Measure Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza-Associated Hospitalizations RFA-IP-15-002
Sponsor: CDCInternal Deadline: 02/02/2015Sponsor Deadline: 03/03/2015Program WebsiteCDC:US Platform to Measure Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza-Associated Hospitalizations RFA-IP-15-002
The goal of this funding announcement is to establish a sustainable network of US institutions that can obtain hospitalization data and provide accurate estimates of annual influenza vaccine effectiveness (VE) to prevent influenza-associated hospitalizations in US adult populations. Participating institutions will coordinate enrollment of adult hospitalized patients with acute respiratory illness (ARI), confirm influenza infection using sensitive laboratory-based molecular assays, and estimate VE using a test-negative study design. Annual VE estimates will be used to inform and assess the public health impact of influenza vaccination programs to prevent health-related complications of influenza infection, especially in older adults. In addition, this network will also compare VE for specific vaccine types available in the US. This network will serve as an emergency response resource in the event of an influenza pandemic to assess VE to prevent hospitalizations.
USC may only submit one application in response to this program announcement. Your application submission MUST be coordinated with the Office of the Vice President for Research. Please send a two page abstract via email to Richard White (email@example.com) by February 2, 2015. In addition to the 2-page abstract, you should also submit a biosketch for the PI.
CDC indicates that a letter of intent is not applicable and a full proposal is due by Mar 3, 2015. For more information: http://www.grants.gov/web/grants/view-opportunity.html?oppId=270970